These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 18575892)
1. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Campeau PM; Foulkes WD; Tischkowitz MD Hum Genet; 2008 Aug; 124(1):31-42. PubMed ID: 18575892 [TBL] [Abstract][Full Text] [Related]
2. Genetic predisposition to breast cancer: past, present, and future. Turnbull C; Rahman N Annu Rev Genomics Hum Genet; 2008; 9():321-45. PubMed ID: 18544032 [TBL] [Abstract][Full Text] [Related]
3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
4. Ten genes for inherited breast cancer. Walsh T; King MC Cancer Cell; 2007 Feb; 11(2):103-5. PubMed ID: 17292821 [TBL] [Abstract][Full Text] [Related]
5. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444 [TBL] [Abstract][Full Text] [Related]
6. Translational advances regarding hereditary breast cancer syndromes. Gage M; Wattendorf D; Henry LR J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895 [TBL] [Abstract][Full Text] [Related]
7. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
8. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management. Kleibl Z; Kristensen VN Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168 [TBL] [Abstract][Full Text] [Related]
9. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182 [TBL] [Abstract][Full Text] [Related]
10. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Byrnes GB; Southey MC; Hopper JL Breast Cancer Res; 2008; 10(3):208. PubMed ID: 18557994 [TBL] [Abstract][Full Text] [Related]
11. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies. Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988 [TBL] [Abstract][Full Text] [Related]
12. Radiotherapy in the treatment of hereditary breast cancer. Pierce LJ; Haffty BG Semin Radiat Oncol; 2011 Jan; 21(1):43-50. PubMed ID: 21134653 [TBL] [Abstract][Full Text] [Related]
13. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Tavtigian SV; Chenevix-Trench G Biomark Med; 2014; 8(4):589-603. PubMed ID: 24796624 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467 [TBL] [Abstract][Full Text] [Related]
15. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272 [TBL] [Abstract][Full Text] [Related]
16. Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China. Cao AY; Hu Z; Shao ZM Breast Cancer Res Treat; 2010 Feb; 120(1):271-2. PubMed ID: 19856097 [No Abstract] [Full Text] [Related]
17. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Baynes C; Healey CS; Pooley KA; Scollen S; Luben RN; Thompson DJ; Pharoah PD; Easton DF; Ponder BA; Dunning AM; Breast Cancer Res; 2007; 9(2):R27. PubMed ID: 17428325 [TBL] [Abstract][Full Text] [Related]
18. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709 [TBL] [Abstract][Full Text] [Related]
19. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Johnson N; Fletcher O; Palles C; Rudd M; Webb E; Sellick G; dos Santos Silva I; McCormack V; Gibson L; Fraser A; Leonard A; Gilham C; Tavtigian SV; Ashworth A; Houlston R; Peto J Hum Mol Genet; 2007 May; 16(9):1051-7. PubMed ID: 17341484 [TBL] [Abstract][Full Text] [Related]